Trastuzumab emtansine (Kadcyla®) HTA ID: 20002
Trastuzumab emtansine (Kadcyla®) is indicated as a single agent, for the adjuvant treatment of adults with HER2-positive, early breast cancer who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2-targeted therapy.
| NCPE Assessment Process | Complete |
| Rapid review commissioned | 20/01/2020 |
| Rapid review completed | 27/02/2020 |
| Rapid Review outcome | A full HTA is recommended to assess the clinical and cost effectiveness of trastuzumab emtansine compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by the HSE | 04/03/2020 |
| Pre-submission consultation with Applicant | 31/03/2020 |
| Full submission received from Applicant | 08/06/2020 |
| Preliminary review sent to Applicant | 29/10/2020 |
| NCPE assessment re-commenced | 30/11/2020 |
| Factual accuracy sent to Applicant | 11/02/2021 |
| NCPE assessment re-commenced | 17/02/2021 |
| NCPE assessment completed | 12/03/2021 |
| NCPE assessment outcome | The NCPE recommends that trastuzumab emtansine (Kadcyla®) be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.